pubmed-article:16337697 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:16337697 | lifeskim:mentions | umls-concept:C1175743 | lld:lifeskim |
pubmed-article:16337697 | lifeskim:mentions | umls-concept:C0014442 | lld:lifeskim |
pubmed-article:16337697 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
pubmed-article:16337697 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
pubmed-article:16337697 | lifeskim:mentions | umls-concept:C1704675 | lld:lifeskim |
pubmed-article:16337697 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
pubmed-article:16337697 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
pubmed-article:16337697 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
pubmed-article:16337697 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
pubmed-article:16337697 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
pubmed-article:16337697 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
pubmed-article:16337697 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:16337697 | pubmed:dateCreated | 2006-1-31 | lld:pubmed |
pubmed-article:16337697 | pubmed:abstractText | Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel coronavirus (SARS-CoV). The binding of SARS-CoV spike (S) protein to cellular angiotensin-converting enzyme 2 (ACE2) is the first step in SARS-CoV infection. Therefore, we assayed the inhibitory effects of small peptides derived from S protein on the binding of S protein to ACE2 and on the S-protein-pseudotyped retrovirus infectivity. SP-4 (residues 192-203), SP-8 (residues 483-494), and SP-10 (residues 668-679) significantly blocked the interaction between S protein and ACE2 by biotinylated enzyme-linked immunosorbent assay, with IC(50) values of 4.30 +/- 2.18, 6.99 +/- 0.71, and 1.88 +/- 0.52 nmol, respectively. Peptide scanning suggested the region spanning residues 660-683 might act as a receptor-binding domain. SP-10 blocked both binding of the S protein and infectivity of S protein-pseudotyped retrovirus to Vero E6 cells. In conclusion, this is the first report of small peptides designed to disrupt the binding of SARS-CoV S protein to ACE2. Our findings suggest that SP-10 may be developed as an anti-SARS-CoV agent for the treatment of SARS-CoV infection. | lld:pubmed |
pubmed-article:16337697 | pubmed:language | eng | lld:pubmed |
pubmed-article:16337697 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16337697 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:16337697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16337697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16337697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16337697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16337697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16337697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16337697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16337697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16337697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16337697 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:16337697 | pubmed:month | Feb | lld:pubmed |
pubmed-article:16337697 | pubmed:issn | 0166-3542 | lld:pubmed |
pubmed-article:16337697 | pubmed:author | pubmed-author:HsiangChien-Y... | lld:pubmed |
pubmed-article:16337697 | pubmed:author | pubmed-author:HoTin-YunTY | lld:pubmed |
pubmed-article:16337697 | pubmed:author | pubmed-author:ChangYung-Hsi... | lld:pubmed |
pubmed-article:16337697 | pubmed:author | pubmed-author:WuShih-LuSL | lld:pubmed |
pubmed-article:16337697 | pubmed:author | pubmed-author:ChengShin-EiS... | lld:pubmed |
pubmed-article:16337697 | pubmed:author | pubmed-author:WeiYen-ChiaoY... | lld:pubmed |
pubmed-article:16337697 | pubmed:author | pubmed-author:LiuHsu-JanHJ | lld:pubmed |
pubmed-article:16337697 | pubmed:author | pubmed-author:ChenJaw-Chyun... | lld:pubmed |
pubmed-article:16337697 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:16337697 | pubmed:volume | 69 | lld:pubmed |
pubmed-article:16337697 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:16337697 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:16337697 | pubmed:pagination | 70-6 | lld:pubmed |
pubmed-article:16337697 | pubmed:dateRevised | 2008-10-23 | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:meshHeading | pubmed-meshheading:16337697... | lld:pubmed |
pubmed-article:16337697 | pubmed:year | 2006 | lld:pubmed |
pubmed-article:16337697 | pubmed:articleTitle | Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction. | lld:pubmed |
pubmed-article:16337697 | pubmed:affiliation | Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan. | lld:pubmed |
pubmed-article:16337697 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:16337697 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16337697 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16337697 | lld:pubmed |